Streetbeat News

INZY

Inozyme Pharma, Inc.

https://www.inozyme.com

Industry

Biotechnology

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Wells Fargo has initiated coverage on Inozyme Pharma (NASDAQ:INZY) with an Overweight rating and a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 2:53 pm

Inozyme Pharma is set to present Phase 1/2 trial data for its drug INZ-701, targeting adults with ENPP1 and ABCC6 deficiencies.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 12:34 pm

Needham analyst Joseph Stringer has reiterated a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $23 price target.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 10:17 am

Inozyme Pharma (NASDAQ:INZY) reported Q1 earnings with losses of $(0.38) per share, missing the consensus estimate of $(0.36) by 5.56%. This represents a 5% improvement over the previous year's losses of $(0.40) per share.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:49 pm

In Monday's after-market session, several health care stocks showed notable movements. GeneDx Holdings led the gainers with a 21.8% increase following their Q1 earnings release, while GlucoTrack experienced the largest decline among the losers, dropping 10.7%. Other notable movers included InnovAge Holding, Mustang Bio, and Vaxxinity, each responding to market dynamics and company-specific news.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 8:31 pm

Needham analyst Joseph Stringer has reiterated a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $23 price target.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 10:43 am

Tilray Brands, Inc. (NASDAQ:TLRY) shares fell by 22% after missing Q3 estimates and revising its fiscal year 2024 outlook. Other stocks showed significant movement, with Laser Photonics Corporation (NASDAQ:LASE) and BioSig Technologies, Inc. (NASDAQ:BSGM) among the top gainers. Vincerx Pharma, Inc. (NASDAQ:VINC) led the losers after presenting preliminary Phase 1 data.

Portfolio Pulse from Avi Kapoor

April 09, 2024 | 5:12 pm

B of A Securities analyst Tazeen Ahmad has maintained a Buy rating on Inozyme Pharma (NASDAQ:INZY) but has lowered the price target from $16 to $14.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 4:38 pm

Needham analyst Joseph Stringer reiterates a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintains a $23 price target.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 11:56 am

Inozyme Pharma, Inc. (NASDAQ:INZY) announced positive topline data from ongoing Phase 1/2 clinical trials of INZ-701 for treating ABCC6 Deficiency (PXE) and ENPP1 Deficiency. The data includes safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy results.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 10:31 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.